Publications
Enhanced or hindered research benefits? A realist review of community engagement and participatory research practices for non-communicable disease prevention in low- and middle-income countries.
Klingberg S, Adhikari B, Draper CE, Bosire E, Nyirenda D, Tiigah P, Mukumbang FC,
- February 10, 2024
Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
Patel PD, Liang Y, Meiring JE, Chasweka N, Patel P, Misiri T, Mwakiseghile F, Wachepa R, Banda HC, Shumba F, Kawalazira G, Dube Q, Nampota-Nkomba N, Nyirenda OM, Girmay T, Datta S, Jamka LP, Tracy JK, Laurens MB, Heyderman RS, Neuzil KM, Gordon MA, TyVAC team,
- February 3, 2024
Fourth Controlled Human Infection Model (CHIM) meeting – CHIMs in endemic countries, May 22-23, 2023.
Kapulu M, Manda-Taylor L, Balasingam S, Means G, Ayiro Malungu M, Bejon P, Chi PC, Chiu C, Church EC, Correa-Oliveira R, Day N, Durbin A, Egesa M, Emerson C, Jambo K, Mathur R, Metzger W, Mumba N, Nazziwa W, Olotu A, Rodgers J, Sinyiza F, Talaat K, Kamerling I, Weller C, Baay M, Neels P,
- February 1, 2024
Prevalence of Endemic Respiratory Viruses During the COVID-19 Pandemic in Urban and Rural Malawi.
Vink E, Banda L, Amoah AS, Kasenda S, Read JM, Jewell C, Denis B, Mwale AC, Crampin A, Anscombe C, Menyere M, Ho A,
- February 1, 2024
Community-level variation in TB testing history in Blantyre, Malawi.
Nightingale ES, Feasey HRA, Khundi M, Soko RN, Burke RM, Nliwasa M, Twabi H, Mpunga JA, Fielding K, MacPherson P, Corbett EL,
- February 1, 2024
Serotype 3 Experimental Human Pneumococcal Challenge (EHPC) study protocol: dose ranging and reproducibility in a healthy volunteer population (challenge 3).
Hazenberg P, Robinson RE, Farrar M, Solorzano C, Hyder-Wright A, Liatsikos K, Brunning J, Fleet H, Bettam A, Howard A, Kenny-Nyazika T, Urban B, Mitsi E, El Safadi D, Davies K, Lesosky M, Gordon SB, Ferreira DM, Collins AM,
- January 10, 2024
Protocol for the challenge non-typhoidal Salmonella (CHANTS) study: a first-in-human, in-patient, double-blind, randomised, safety and dose-escalation controlled human infection model in the UK.
Smith C, Smith E, Rydlova A, Varro R, Hinton JCD, Gordon MA, Choy RKM, Liu X, Pollard AJ, Chiu C, Cooke GS, Gibani MM,
- January 10, 2024
Mosquito control by abatement programmes in the United States: perspectives and lessons for countries in sub-Saharan Africa.
Ochomo E, Rund SSC, Mthawanji RS, Antonio-Nkondjio C, Machani M, Samake S, Wolie RZ, Nsango S, Lown LA, Matoke-Muhia D, Kamau L, Lukyamuzi E, Njeri J, Chabi J, Akrofi OO, Ntege C, Mero V, Mwalimu C, Kiware S, Bilgo E, Traoré MM, Afrane Y, Hakizimana E, Muleba M, Orefuwa E, Chaki P, Juma EO,
- January 4, 2024
Mass drug administration campaigns: comparing two approaches for schistosomiasis and soil-transmitted helminths prevention and control in selected Southern Malawi districts.
Makaula P, Kayuni SA, Mamba KC, Bongololo G, Funsanani M, Juziwelo LT, Musaya J, Furu P,
- January 3, 2024
Prospective multicentre accuracy evaluation of the FUJIFILM SILVAMP TB LAM test for the diagnosis of tuberculosis in people living with HIV demonstrates lot-to-lot variability.
Székely R, Sossen B, Mukoka M, Muyoyeta M, Nakabugo E, Hella J, Nguyen HV, Ubolyam S, Chikamatsu K, Macé A, Vermeulen M, Centner CM, Nyangu S, Sanjase N, Sasamalo M, Dinh HT, Ngo TA, Manosuthi W, Jirajariyavej S, Mitarai S, Nguyen NV, Avihingsanon A, Reither K, Nakiyingi L, Kerkhoff AD, MacPherson P, Meintjes G, Denkinger CM, Ruhwald M, FujiLAM Study Consortium,
- January 1, 2024